Lily Wound



Lily Wound provides strategic advice on the most important issues facing emerging and mid-sized life sciences companies today. She has extensive experience representing pharmaceutical, biotechnology, vaccine and other life sciences clients on a wide range of complex commercial, corporate and licensing transactions. She has worked on transactions at all stages of a life sciences product's life cycle. In addition to life sciences, Ms. Wound has developed an exceptional practice representing domestic and international clients in other industries—such as those in the healthcare, cosmetics, publishing, media, Internet, software and technology industries—in a variety of corporate transactions. Ms. Wound understands the complexities of their businesses and provides solutions-oriented advice on issues that affect them.

Prior to joining WilmerHale, Ms. Wound was a counsel at another law firm in New York where she focused on biotechnology and life sciences matters. During that time she also developed and organized a “Building a Successful Startup” boot camp event for the Cornell Center for Technology Enterprise and Commercialization. Previously, Ms. Wound served as in-house counsel for Hearst Corporation, where she advised on all aspects of Hearst's businesses relating to traditional media, new media, digital media and healthcare information and technology. Her responsibilities at Hearst included serving as general counsel for an evidence-based medical information and technology company and leading all complex transactions in the newspapers division.

Professional Activities

Ms. Wound serves on the National Committee for Women in Bio, a networking organization for professional women in the life sciences. In this capacity, she is the National Chair for Young Women in Bio, a volunteer organization that encourages young girls to study and pursue careers in the STEM sciences. She is also on the Steering Committee of the Women in Bio-Metro NY Chapter.

Publications & News


March 14, 2018

WilmerHale Counsels Voyager Therapeutics in Global Strategic Collaboration with AbbVie

Voyager Therapeutics, Inc., a clinical-stage gene therapy company, and AbbVie, a global biopharmaceutical company, announced that they have entered into an exclusive strategic collaboration and option agreement to develop and commercialize vectorized antibodies directed against tau for the treatment of Alzheimer's disease and other neurodegenerative diseases.

January 26, 2018

WilmerHale Represents Spark Therapeutics in Licensing and Supply Agreement With Novartis

Spark Therapeutics, a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, announced it has entered into a licensing agreement with Novartis Pharmaceuticals to develop and commercialize investigational voretigene neparvovec outside the United States.

December 15, 2016

WilmerHale Reps Spark Therapeutics in Licensing Agreement with Selecta Biosciences

Spark Therapeutics and Selecta Biosciences, Inc. announced a license agreement that provides Spark Therapeutics with exclusive worldwide rights to Selecta's proprietary Synthetic Vaccine Particles platform technology for co-administration with gene therapy targets.

Speaking Engagements


Skip Navigation Links.


JD, George Washington University Law School

MPH, Boston University

BA, Biochemical Sciences, Harvard University

Bar Admissions

New York


Chinese (Mandarin)

Skip Navigation Links.